Form D · Biotechnology
Coriell Life Sciences, Inc.
Philadelphia, PA · CIK 0001675480
Offering snapshot reported May 6, 2019 · SEC filing
- Reported sold
- $9.47M Offering amount: $10M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 26, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 6, 2019 | Initial | $9,467,925 | No comparison | 4 | SEC filing |
| Jul 19, 2016 | Initial | $605,000 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-338841
Source: Form D, filed May 6, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Stephen Andriole | Director |
| Dr. Stephen Andriole | Director |
| Michael F. Christman | Director |
| Peter Driscoll | Director |
| Scott Megill | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4747 South Broad Street Building 101, Suite 222
Philadelphia, PA, 19112
Philadelphia, PA, 19112